“diabetic-macular-edema” Archives

in
Entry Author Date Location
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More 09/18/20 National
Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug 09/15/20 San Francisco
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue 09/09/20 National
Unity Biotech Arthritis Drug Flunks Phase 2, Spelling Program’s End 08/18/20 San Francisco
AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis 06/24/20 National
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More 12/13/19 National
KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test 12/10/19 Boston
As AMD Race Tightens, Regeneron’s Second Eye Drug Combo Falls Short 11/27/17 New York
KalVista, Merck Partnership on Blindness Drug Sends Shares Skyward 10/10/17 Boston
On Front Lines Of Price Dispute, Eye Doctors Wary of New Drug Data 11/01/16 National
Eleven Bio’s Eye Disease Drug Set For $22.5M Milestone from Roche 07/08/16 Boston
Eleven Bio, Still Breathing, Sells Eye Drug to Roche 06/13/16 Boston
East Coast Biotech Roundup: Alkermes, Zafgen, Snowmaggedon & More 01/22/16 Boston
With Second Eye Drug Flop, Eleven Heads Back to Drawing Board 01/19/16 Boston
Eleven Bio’s Shares Routed as Dry Eye Drug Flunks Phase 3 Test 05/18/15 Boston
West Coast Biotech Roundup: Laguna, SeaGen, Unchained, DME & More 02/19/15 San Francisco
East Coast Biotech Roundup: Intarcia, Atlas, Visterra, & More 10/06/14 Boston
East Coast Biotech Roundup: Emulate, Accelerator, Retrophin, & More 08/01/14 Boston
Avalanche Bio Rolls Onto Nasdaq After Upsized, $102M IPO 07/31/14 San Francisco
Eleven Prices IPO Below Projected Range, Grabs $50M 02/06/14 Boston
East Coast Biotech Roundup: Curoverse, Sia, Trinity, & (Much) More 12/20/13 Boston
PSivida, Alimera Shares Fall as FDA Rejects Eye Drug for Third Time 10/18/13 Boston
East Coast Life Sciences Roundup: Moderna, Inotek, Roche, & More 10/04/13 Boston
East Coast Life Sciences Roundup: KiiLN, Celgene, Acceleron, & More 08/09/13 New York
Regeneron Targets New Market for Blockbuster Eye Drug 08/06/13 New York
Genentech Gets FDA OK of Lucentis for Diabetic Eye Disease 08/10/12 San Francisco
Genentech Eye Drug, Under Scrutiny, Passes Study in Diabetic Patients to Open Up New Market 03/25/11 San Francisco
Page 1 of 1